140 related articles for article (PubMed ID: 17119488)
1. [Evidence data and importance of public health of the new antipsychotics].
Launois R
Encephale; 2006 Oct; 32(5 Pt 3):S861-5. PubMed ID: 17119488
[No Abstract] [Full Text] [Related]
2. Improving mental health treatments through comparative effectiveness research.
Wang PS; Ulbricht CM; Schoenbaum M
Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
[TBL] [Abstract][Full Text] [Related]
4. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Nyhuis AW; Faries DE; Kinon BJ; Baker RW; Shekhar A
Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.
Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
BMC Psychiatry; 2009 Sep; 9():54. PubMed ID: 19725969
[TBL] [Abstract][Full Text] [Related]
6. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
Gau SS; Chung CH; Gau CS
J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of schizophrenia pharmacotherapy.
Soumerai SB; Law MR
Am J Psychiatry; 2007 Apr; 164(4):678; author reply 678-9. PubMed ID: 17403984
[No Abstract] [Full Text] [Related]
8. Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.
Barbosa WB; Costa JO; de Lemos LLP; Gomes RM; de Oliveira HN; Ruas CM; Acurcio FA; Barbui C; Bennie M; Godman B; Guerra AA
Appl Health Econ Health Policy; 2018 Oct; 16(5):697-709. PubMed ID: 30051254
[TBL] [Abstract][Full Text] [Related]
9. The functionality and economic costs of outpatients with schizophrenia in Taiwan.
Lee IH; Chen PS; Yang YK; Liao YC; Lee YD; Yeh TL; Yeh LL; Cheng SH; Chu CL
Psychiatry Res; 2008 Apr; 158(3):306-15. PubMed ID: 18243334
[TBL] [Abstract][Full Text] [Related]
10. Is a guideline based treatment cost-effective for a middle income country? Results from a study with Mexican adolescents.
Ayala L; Sauer T; Ulloa RE
Schizophr Res; 2018 Feb; 192():485-486. PubMed ID: 28601501
[No Abstract] [Full Text] [Related]
11. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain. Description and associated factors. The Psychosp study.
Peiró S; Gómez G; Navarro M; Guadarrama I; Rejas J;
Soc Psychiatry Psychiatr Epidemiol; 2004 Jul; 39(7):507-13. PubMed ID: 15243687
[TBL] [Abstract][Full Text] [Related]
12. New vs. old antipsychotics: the Texas experience.
Reid WH
J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
14. The costs of drugs for schizophrenia.
Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
[No Abstract] [Full Text] [Related]
15. [Priority for atypical antipsychotics--comments on the article by Dose M. Priority for Atypicals? Current studies clarify some aspects. Psychiat Prax 2007; 34:46-49].
Fritze J; Aldenhoff J; Bergmann F; Eckermann G; Maier W; Möller HJ; Gaebel W
Psychiatr Prax; 2008 Mar; 35(2):94-7; author reply 97-8. PubMed ID: 17987542
[No Abstract] [Full Text] [Related]
16. Impact of splitting risperidone tablets on medication adherence and on clinical outcomes for patients with schizophrenia.
Weissman EM; Dellenbaugh C
Psychiatr Serv; 2007 Feb; 58(2):201-6. PubMed ID: 17287376
[TBL] [Abstract][Full Text] [Related]
17. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system.
Reid WH; Mason M
J Clin Psychiatry; 1998 Apr; 59(4):189-94. PubMed ID: 9590670
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
Polsky D; Doshi JA; Bauer MS; Glick HA
Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
[TBL] [Abstract][Full Text] [Related]
19. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
Meltzer D
J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
